Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nicorette® Gum
Nicotine Gum · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Nicotine gum | EXPERIMENTAL | Nicotine gum |
| Placebo gum | PLACEBO_COMPARATOR | Placebo gum |
| Nicotine inhaler | ACTIVE_COMPARATOR | Nicotine inhaler |
| Placebo inhaler | PLACEBO_COMPARATOR | Placebo inhaler |
| Name | Type | Description |
|---|---|---|
| Nicotine gum | DRUG | 8-12 pieces per day, maximum 24 daily |
| Placebo gum | DRUG | 8-12 pieces per day, maximum 24 daily |
| Nicotine inhaler | DRUG | 6-12 cartridges per day, maximum 12 daily |
| Placebo inhaler | DRUG | 6-12 cartridges per day, maximum 12 daily |
Inclusion Criteria: * Age above 18 * Smoking \>/= 15 cigarettes/day * Having smoked for 3 years or more * CO \>/= 10ppm at inclusion * Want to reduce smoking * Prepared to adhere to the protocol * Willing to provide signed informed consent * Having made at least one serious attempt to quit smoking ...
Nicotine gum is used for smoking cessation, helping people reduce or quit cigarette smoking. It is a nicotine replacement therapy developed by Johnson & Johnson, which trades under the ticker JNJ. The gum falls within the psychiatry therapeutic area and is classified as a small molecule.
Nicotine gum works as an agonist at the CHRNB2 and CHRNA4 nicotinic acetylcholine receptor targets. By delivering nicotine through the buccal mucosa, it stimulates these receptors to ease withdrawal symptoms and cravings when a person stops smoking. This supports smoking reduction or cessation as part of a quit attempt.
Nicotine gum is developed by Johnson & Johnson, which trades under the ticker JNJ. The company is the developer associated with this nicotine replacement therapy product for smoking cessation.
Nicotine gum has been studied in Phase 3 clinical development for smoking cessation. It is an investigational asset in this dataset rather than a newly approved product, and its recorded trial activity has concluded. One Phase 3 trial has been completed, with no active trials currently listed.
Nicotine gum has been evaluated in the completed Phase 3 trial NCT00840242, titled Smoking Reduction or Cessation With Nicotine Replacement Therapy. That trial enrolled 314 participants in Czechia, was randomized, double blind, and placebo controlled, and included adults aged 18 years and older of all sexes.
Nicotine gum is a form of nicotine replacement therapy, a broader category of products that deliver nicotine to help people quit smoking. The completed Phase 3 trial NCT00840242 studied smoking reduction or cessation with nicotine replacement therapy, and nicotine gum is one such delivery method within that class.